High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent

Journal of Pathology

Volumn 198, Issue 4, 2002, Pages 468-475

  Oudejans, Joost J ^a   Harijadi, Hari ^b   Kummer, J Alain ^a   Tan, I Bing ^c   Bloemena, Elizabeth ^a   Middeldorp, Jaap M ^a   Bladergroen, Belinda ^a   Dukers, Danny F ^a   Vos, Wim ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Immune response; MHC class I; Prognosis; Serine protease inhibitor

Indexed keywords

ANTIBODY; CD56 ANTIGEN; CD8 ANTIGEN; ENZYME INHIBITOR; GRANZYME B; IMMUNOGLOBULIN HEAVY CHAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN PI 9; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER MORTALITY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDONESIA; LEUKOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; NASOPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY;

ADULT; ANTIGENS, CD8; BIOPSY; DISEASE-FREE SURVIVAL; FEMALE; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERINE ENDOPEPTIDASES; SERPINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036899460     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1236     Document Type: Article

References (33)

1. Sung NS, Edwards RH, Seillier-Moiseiwitsch F, Perkins AG, Zen Y, Raab-Traub N. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer 1998; 76: 207-215.
2. Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18: 1324-1330.
3. Fandi A, Cvitkovic E. Biology and treatment of nasopharyngeal cancer. Curr Opin Oncol 1995; 7: 255-263.
4. zur Hansen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228: 1056-1058.
5. Gunven P, Klein G, Henle G, Henle W, Clifford P. Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature 1970; 228: 1053-1056.
6. Klein G. Viral latency and transformation: the strategy of Epstein-Barr virus. Cell 1989; 58: 5-8.
7. Trivedi P, Hu LF, Chen F, et al. Epstein-Barr virus (EBV)-encoded membrane protein LMPl from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 1994; 30A: 84-88.
8. Ferradini L, Miescher S, Stoeck M, et al. Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma. Int J Cancer 1991; 47: 362-370.
9. Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998; 58: 310-314.
10. Lee SP, Chan AT, Cheung ST, et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL response in the blood and tumours of NPC patients and the antigen-processing function of the tumour cells. J Immunol 2000; 165: 573-582.
11. Graubert TA, Ley TJ. How do lymphocytes kill tumour cells? Clin Cancer Res 1996; 2: 785-789.
12. + as well as CD8+ cytotoxic T lymphocytes in humans. Blood 2000; 95: 2352-2355.
13. Bird CH, Sutton VR, Sun J, et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18: 6387-6398.
14. Tombolini V, De Sanctis V, Donato V, et al. Prognostic features and treatment outcome in patients with nasopharyngeal carcinoma: an experience of 20 years. Anticancer Res 2001; 21: 1413-1418.
15. Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys 2001; 50: 1181-1189.
16. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours (5th edn). UICC: Geneva, 1997.
17. Shanmugaratnam K, Sobin LH. Histologic typing of tumours of the upper respiratory tract and ear. In International Histologic Classification (2nd edn). Springer-Verlag: Berlin, 1991; 32-33.
18. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJ, Hack CE. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 1995; 100: 164-172.
19. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 1996; 87: 3844-3851.
20. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies crossreact with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 1998; 35: 177-188.
21. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin fixed, paraffin embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 113-125.
22. Bladergroen BA, Strik MC, Bovenschen N, et al. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 2001; 166: 3218-3225.
23. Cox DR. Regression models and life tables. J R Stat Soc 1972; B34: 187.
24. Lee AWM, Foo W, Law SCK, et al. Staging of nasopharyngeal carcinoma: from Ho's to the new UICC system. Int J Cancer (Pred Oncol) 1999; 84: 179-187.
25. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 1376-1382.
26. ten Berge RL, Dukers DF, Oudejans JJ, et al. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999; 93: 2688-2696.
27. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
28. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997; 90: 3118-3129.
29. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumour cells. Cell Death Differ 1999; 6: 471-480.
30. Boesen-de Cock JG, Tepper AD, de Vries E, van Blitterswijk WJ, Borst J. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J Biol Chem 1999; 274: 14255-14261.
31. Yao Y, Minter HA, Chen X, Reynolds GM, Bromley M, Arrand JR. Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int J Cancer 2000; 88: 949-955.
32. Yao M, Ohshima K, Suzumiya J, Kume T, Shiroshita T, Kikuchi M. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1997; 72: 398-402.
33. Beck A, Pazolt D, Grabenbauer GG, et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. J Pathol 2001; 194: 145-151.